- Cyclo Therapeutics press release (NASDAQ:CYTH): Q3 net loss of $4.2M.
- The company expects research and development to further increase in 2022 as we continue to seek regulatory approval for the use of Trappsol® Cyclo™ in the treatment of NPC and Alzheimer’s disease.
- The company ended the quarter with approximately $4.3M of cash.
- Shares +7.5% PM.
Cyclo Therapeutics reports Q3 results
Recommended For You
More Trending News
About CYTH Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CYTH | - | - |
Cyclo Therapeutics, Inc. |